Terminal
Spotlight
Cashu Research

← Back to Terminal

Stocks
Healthcare
NASDAQ
PSNL

Market Cap: $1.71B

PI

Personalis, Inc.

PSNL

NASDAQ (NASDAQ Global Market)USD

Overview News Analyst Reports Financials Politician Trades Insider Trades Executive

By Cashu Finance. Providing market news, analysis, and research for investors worldwide.

Company

Stocks About Advertisers Brokers Contact

Legal

Terms of Service Privacy Policy

© 2026 Cashu Technologies Pty Ltd. All rights reserved. Cashu Finance is a trademark of Cashu Technologies Pty Ltd.

The content published on Cashu Finance is for informational purposes only and should not be construed as investment advice, a recommendation, or an offer to buy or sell any securities. All opinions expressed are those of the authors and do not reflect the official position of Cashu Technologies Pty Ltd or its affiliates. Past performance is not indicative of future results. Investing involves risk, including the possible loss of principal. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions.

Cashu Finance and its contributors may hold positions in securities mentioned in published content. Any such holdings will be disclosed at the time of publication. Market data is provided on an "as-is" basis and may be delayed. Cashu Technologies Pty Ltd does not guarantee the accuracy, completeness, or timeliness of any information presented.

Cashu Research is part of Cashu Technology Pty Ltd, which is an authorised representative (AR # 001318029) of Adviser Solutions Group Pty Ltd (ABN 88 601 875 521) (AFSL 485946) (ASG).

This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by Cashu Technologies Pty Ltd, any of their related body corporates or any other person. To the maximum extent possible, Cashu Technologies Pty Ltd, their related body corporates or any other person do not accept any liability for any statement in this material.

News

Personalis Revolutionizes Cancer Treatment with Advanced Personalized Genomics Solutions

Personalis Advances Cancer Management with Personalized Genomics Personalis, Inc., a prominent player in the field of advanced genomics based in Fremont, California, continues to make strides in cance…

Cashu Finance·over 1 year ago

Personalis Innovates Cancer Care with Advanced Genomic Profiling Solutions

Personalis Advances Cancer Management Through Innovative Genomic Profiling Personalis, Inc., a pioneer in advanced genomics based in Fremont, California, is at the forefront of transforming cancer man…

Cashu Finance·over 1 year ago

Personalis Showcases Precision Oncology Innovations at BTIG Conference 2025

Personalis Emphasizes Innovation in Precision Oncology at Upcoming Conference Personalis, Inc., a leading biotechnology firm based in Fremont, California, is poised to showcase its innovative advancem…

Cashu Finance·over 1 year ago

Personalis Advances Lung Cancer Detection with Ultra-Sensitive ctDNA Testing Breakthrough

Breakthrough in Early Lung Cancer Detection Using Ultra-Sensitive ctDNA Testing Personalis, Inc. is making waves in the oncology landscape through its collaboration with Professor Charles Swanton and…

Cashu Finance·almost 2 years ago

Personalis Advances Lung Cancer Detection with NeXT Personal and Leading Research Collaboration

Personalis Partners with Leading Researchers to Advance Lung Cancer Detection Personalis, Inc. collaborates with Professor Charles Swanton and his research team from the Francis Crick Institute and Un…

Cashu Finance·almost 2 years ago

Personalis Reports 15% Revenue Growth in Precision Oncology for 2024 Performance

Personalis Reports Strong Revenue Growth in Precision Oncology Personalis, Inc., a leader in advanced genomics for precision oncology, announces its preliminary revenue results for the fourth quarter…

Cashu Finance·almost 2 years ago

Personalis Reports 15% Revenue Growth in Precision Oncology for 2024

Personalis Reports Strong Revenue Growth in Precision Oncology for 2024 Personalis, Inc., a prominent player in advanced genomics focused on precision oncology, announces preliminary revenue results f…

Cashu Finance·almost 2 years ago

Personalis Expands Tempus Partnership to Enhance Cancer Diagnostics and MRD Testing Access

Expansion of Collaboration to Enhance Cancer Diagnostics Personalis, Inc. and Tempus AI, Inc. are expanding their commercial partnership, originally established in November 2023, to enhance the availa…

Cashu Finance·almost 2 years ago

Personalis Expands Partnership with Tempus to Enhance MRD Testing for Cancer Management

Strengthening Cancer Management Through Innovative Partnerships Personalis, Inc. and Tempus AI, Inc. have announced a significant expansion of their commercial partnership to enhance the availability…

Cashu Finance·almost 2 years ago

Personalis Showcases Precision Oncology Innovations at Upcoming Investor Conferences

Personalis Advances Precision Oncology Through Upcoming Conferences Fremont-based Personalis, Inc., a frontrunner in advanced genomics, is set to showcase its innovations in precision oncology at two…

Cashu Finance·almost 2 years ago

Personalis Innovates Cancer Care with Advanced Testing Solutions for Precision Oncology

Personalis Advances Precision Oncology Through Innovative Testing Solutions Personalis, Inc., a frontrunner in the field of advanced genomics for precision oncology, is making significant strides in t…

Cashu Finance·almost 2 years ago